depression – pharmaceutical daily

March 20, 2019 Off

Sage Therapeutics gets approval for Zulresso, first new drug to treat postpartum depression

Sage Therapeutics got clearance from the FDA has approved Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD), and is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth.

March 18, 2019 Off

Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U.S. FDA for Breakthrough Treatment of Depression

By BusinessWire

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression.

April 7, 2017 Off

The World Health Day 2017: recognizing and treating depression

By Dino Mustafić

Major depressive disorder or clinical depression, or simply depression is defined as a common but serious mood disorder. It causes severe …